Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Cut to $35.00 by Analysts at Truist Financial

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price decreased by Truist Financial from $37.00 to $35.00 in a research report report published on Friday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently commented on AGIO. Bank of America upped their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, September 21st. JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. HC Wainwright boosted their price target on Agios Pharmaceuticals from $55.00 to $62.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday, September 21st. Finally, TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.12.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO traded up $1.14 during mid-day trading on Friday, hitting $29.41. The stock had a trading volume of 1,281,176 shares, compared to its average volume of 1,338,915. Agios Pharmaceuticals has a 1 year low of $22.24 and a 1 year high of $46.00. The business has a 50 day moving average price of $33.27 and a two-hundred day moving average price of $31.76. The firm has a market cap of $1.76 billion, a P/E ratio of -4.65 and a beta of 0.66.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.15. The business had revenue of $55.39 million during the quarter, compared to analysts’ expectations of $51.65 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. Equities research analysts predict that Agios Pharmaceuticals will post -5.85 EPS for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the company’s stock in a transaction on Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the completion of the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. This represents a 12.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Agios Pharmaceuticals in the second quarter worth about $239,582,000. Assenagon Asset Management S.A. lifted its holdings in Agios Pharmaceuticals by 1,714.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after buying an additional 1,782,457 shares during the period. ADAR1 Capital Management LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $47,800,000. Dimensional Fund Advisors LP boosted its position in Agios Pharmaceuticals by 14.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,151,614 shares of the biopharmaceutical company’s stock valued at $38,940,000 after acquiring an additional 147,273 shares in the last quarter. Finally, Parkman Healthcare Partners LLC bought a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $24,828,000.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: Agios reported a loss of $1.09 per share, narrower than analyst estimates, while revenue of $55.39 million topped the $51.65 million consensus. The per-share loss also improved from $1.78 a year earlier. Agios Q3 results and business update
• Positive Sentiment: Mitapivat growth and regulatory milestone: Mitapivat revenue increased more than fourfold, and an FDA decision on the drug for sickle-cell disease is expected in February 2027. Strong sales and a potential approval could support future growth, though the FDA outcome remains uncertain. Mitapivat revenue and FDA timeline
• Positive Sentiment: HC Wainwright raised its target: The firm lifted its price target from $55 to $62 and maintained a Buy rating, signaling substantial expected upside from the cited share price. HC Wainwright recommendations
• Neutral Sentiment: Truist lowered its target but kept a Buy rating: Truist cut its target from $37 to $35, while continuing to see upside from the cited price. The reduction tempers, but does not reverse, its positive stance. Truist recommendations
• Negative Sentiment: Planned R&D workforce reductions: Agios aims to eliminate more than 100 R&D roles. Cuts could reduce costs, but may also raise concerns about research capacity and execution as the company approaches a key regulatory decision. Agios R&D job cuts

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.